DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia

Terminated

Conditions: Chronic Lymphocytic Leukemia (CLL)

First Posted Date: 2020-12-07

Last Posted Date: 2022-10-26

Lead Sponsor: AbbVie

Target Recruit Count: 5

Registration Number: NCT04655261

Locations: 🇷🇺
Tula Regional Clinical Hospital /ID# 231128, Tula, Russian Federation
🇷🇺
Russian Research Institute of Hematology and Transfusiology of the FMBA /ID# 231127, Sankt-Peterburg, Russian Federation
🇷🇺
Moscow State budget healthcare /ID# 226058, Moscow, Moskva, Russian Federation

and more 1 locations

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

Phase 1

Completed

Conditions: CoronaVirus Disease-2019 (COVID-19)

Interventions: Drug: ABBV-47D11
Drug: Placebo for ABBV-47D11
Drug: ABBV-2B04
Drug: Placebo for ABBV-2B04

First Posted Date: 2020-11-25

Last Posted Date: 2021-09-02

Lead Sponsor: AbbVie

Target Recruit Count: 25

Registration Number: NCT04644120

Locations: 🇺🇸
Beautiful Minds Clinical Research Center /ID# 228708, Cutler Bay, Florida, United States
🇺🇸
Glendale Adventist Medical Center /ID# 225188, Glendale, California, United States
🇺🇸
Triple O Research Institute /ID# 228612, West Palm Beach, Florida, United States

and more 15 locations

Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease Symptoms in Adult Female Participants With Moderate to Severe Endometriosis-associated Pain

Completed

Conditions: Endometriosis

First Posted Date: 2020-11-16

Last Posted Date: 2025-04-01

Lead Sponsor: AbbVie

Target Recruit Count: 117

Registration Number: NCT04630990

Locations: 🇮🇱
Kaplan Medical Center /ID# 224773, Rekhovot, HaMerkaz, Israel
🇮🇱
Soroka University Medical Center /ID# 224774, Be'er Sheva, HaDarom, Israel
🇮🇱
Yitzhak Shamir Medical Center /ID# 224768, Zerifin, HaMerkaz, Israel

and more 7 locations

A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois

Completed

Conditions: Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2)

First Posted Date: 2020-11-02

Last Posted Date: 2022-10-10

Lead Sponsor: AbbVie

Target Recruit Count: 1007

Registration Number: NCT04611230

Locations: 🇺🇸
Great Lakes Clinical Trials /ID# 224874, Chicago, Illinois, United States

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Phase 3

Active, not recruiting

Conditions: Schizophrenia
Autism Spectrum Disorder (ASD)
Bipolar I Disorder

Interventions: Drug: Cariprazine Flexible Dose

First Posted Date: 2020-10-08

Last Posted Date: 2024-10-18

Lead Sponsor: AbbVie

Target Recruit Count: 310

Registration Number: NCT04578756

Locations: 🇺🇸
Harmonex Neuroscience Research /ID# 234938, Dothan, Alabama, United States
🇺🇸
Pillar Clinical Research /ID# 236434, Bentonville, Arkansas, United States
🇺🇸
Advanced Research Center /ID# 241903, Anaheim, California, United States

and more 39 locations

Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response

Completed

Conditions: Hepatitis C Virus (HCV)

First Posted Date: 2020-10-08

Last Posted Date: 2023-08-14

Lead Sponsor: AbbVie

Target Recruit Count: 42

Registration Number: NCT04577482

Locations: 🇷🇺
Irkutsk Regional Center for the Prevention and Control of AIDS and Infections /ID# 229509, Irkutsk, Russian Federation
🇷🇺
Infectious Clinical Hosp #1 /ID# 225063, Moscow, Russian Federation
🇷🇺
Infectious Clinical Hospita l#2 /ID# 243217, Nizhniy Novgorod, Russian Federation

and more 7 locations

A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis (RA)

First Posted Date: 2020-10-05

Last Posted Date: 2024-10-02

Lead Sponsor: AbbVie

Target Recruit Count: 413

Registration Number: NCT04574492

Locations: 🇨🇦
Dr. Jonathan D. Chan Inc. /ID# 222976, Vancouver, British Columbia, Canada
🇨🇦
Eastern Regional Health Authority /ID# 223911, St. John's, Newfoundland and Labrador, Canada
🇨🇦
Fraser Clinical Trials Inc /ID# 225200, New Westminster, British Columbia, Canada

and more 36 locations

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Eftozanermin alfa
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2020-09-30

Last Posted Date: 2025-05-16

Lead Sponsor: AbbVie

Target Recruit Count: 4

Registration Number: NCT04570631

Locations: 🇺🇸
Duplicate_Emory University, Winship Cancer Institute /ID# 222922, Atlanta, Georgia, United States
🇺🇸
Norton Healthcare Pavilion /ID# 222918, Louisville, Kentucky, United States
🇺🇸
Dana-Farber Cancer Institute /ID# 222174, Boston, Massachusetts, United States

and more 16 locations

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

Phase 2

Recruiting

Conditions: Diabetic Retinopathy (DR)
Center-Involved Diabetic Macular Edema (CI-DME)

Interventions: Genetic: ABBV-RGX-314 Dose 1
Genetic: ABBV-RGX-314 Dose 2
Genetic: ABBV-RGX-314 Dose 3
Biological: Aflibercept
Drug: Topical Steroid
Genetic: ABBV-RGX-314 Dose 4

First Posted Date: 2020-09-28

Last Posted Date: 2025-03-19

Lead Sponsor: AbbVie

Target Recruit Count: 130

Registration Number: NCT04567550

Locations: 🇺🇸
Barnet Dulaney Perkins Eye Center, Phoenix, Arizona, United States
🇺🇸
Springfield Clinic, Springfield, Illinois, United States
🇺🇸
Retina Research Institute of Texas, LLC, Abilene, Texas, United States

and more 21 locations

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

Phase 1

Completed

Conditions: Human Immunodeficiency Virus (HIV)

Interventions: Drug: ABBV-382
Drug: Placebo for ABBV-382

First Posted Date: 2020-09-18

Last Posted Date: 2024-03-04

Lead Sponsor: AbbVie

Target Recruit Count: 54

Registration Number: NCT04554966

Locations: 🇵🇷
Clinical Research Puerto Rico /ID# 223923, San Juan, Puerto Rico
🇺🇸
Central Texas Clinical Research /ID# 223378, Austin, Texas, United States
🇵🇷
Ponce Medical School Foundation /ID# 224231, Ponce, Puerto Rico

and more 18 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy